[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
The multi-center non-randomized clinical study included 38 patients, aged 31-70, with morphologically (histologically and/or cytologically) verified diagnosis of disseminated cutaneous melanoma established objective response in 18.5% and clinically significant effect (55.5%) following first-line treatment with fotemustine in conjunction with cisplatin and tamoxifen. Fotemustine as a first-line component of combination chemotherapy retarded metastatic spread to the brain. Since side-effects incidence was not high, the regimen may be used under outpatient hospital conditions.